Citation

Ben Shimon M, Shavit-Stein E, Altman K, Pick CG, Maggio N. Front. Pharmacol. 2019; 10: e1532.

Affiliation

Talpiot Medical Leadership Program, The Chaim Sheba Medical Center, Ramat Gan, Israel.

Copyright

(Copyright © 2019, Frontiers Media)

DOI

10.3389/fphar.2019.01532

PMID

32009953

PMCID

PMC6971217

Abstract

Traumatic brain injury (TBI) commonly leads to development of seizures, accounting for approximately 20% of newly diagnosed epilepsy. Despite the high clinical significance, the mechanisms underlying the development of posttraumatic seizures (PTS) remain unclear, compromising appropriate management of these patients. Accumulating evidence suggest that thrombin, the main serine protease of the coagulation cascade, is involved in PTS genesis by mediating inflammation and hyperexcitability following blood brain barrier breakdown. In order to further understand the role of thrombin in PTS, we generated a combined mild TBI (mTBI) and status epilepticus mice model, by injecting pilocarpine to mice previously submitted to head injury. Interestingly, mTBI was able to reduce seizure onset in the pilocarpine animal model as well as increase the death rate in the treated animals. In turn, pilocarpine worsened spatial orientation of mTBI treated mice. Finally, thrombin activity as well as the expression of IL1-β and TNF-α was significantly increased in the mTBI-pilocarpine treated animals. In conclusion, these observations indicate a synergism between thrombin and mTBI in lowering seizure in the pilocarpine model and possibly aggravating inflammation. We believe that these results will improve the understanding of PTS pathophysiology and contribute to the development of more targeted therapies in the future.

Copyright © 2020 Ben Shimon, Shavit-Stein, Altman, Pick and Maggio.

Language: en

Keywords

N-Methyl-D-Aspartate (NMDA); Protease Activated Receptor 1 (PAR1); epilepsy; mild traumatic brain injury; thrombin